U.S. market Closed. Opens in 9 hours 10 minutes

ANEB | Anebulo Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.4301 - 1.6100
52 Week Range 1.2500 - 3.30
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 5,936
Average Volume 9,193
Shares Outstanding 25,933,200
Market Cap 37,343,808
Sector Healthcare
Industry Biotechnology
IPO Date 2021-05-07
Valuation
Profitability
Growth
Health
P/E Ratio -4.80
Forward P/E Ratio N/A
EPS -0.30
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 2
Country USA
Website ANEB
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
*Chart delayed
Analyzing fundamentals for ANEB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ANEB Fundamentals page.

Watching at ANEB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ANEB Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙